Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Launches its Corporate Website's New Modalities~Approach for Cell and Gene Therapies~ Section

08/30/2021 | 09:32pm EDT

We, at Astellas, are actively advancing new modalities/technologies based on our research and development strategy, the Focus Area Approach.
Here we introduce our initiatives on Cell and Gene Therapies -where we concentrate our R&D investments -the foundational technologies and capabilities of each respective platform, and our strategic approach.

In recent years, Cell and Gene Therapies have started to become a reality with innovative new treatments for diseases being developed. Aspiring to bring life-changing treatments to patients suffering from diseases that lack treatment options, Astellas focuses on the potential of Cell and Gene Therapies. These therapies may have the potential to transform patients' lives and cure diseases in one or only a few treatments by addressing the root cause of the diseases rather than the symptoms. The therapies have the potential to resolve unmet medical needs and provide new VALUE to patients, their families, and society.

Disclaimer

Astellas Pharma Inc. published this content on 31 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 August 2021 01:31:03 UTC.


© Publicnow 2021
All news about ASTELLAS PHARMA INC.
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
09/30ASTELLAS PHARMA : Corporate Strategic Plan 2021—dedicated to realization
PU
More news
Financials
Sales 2022 1 325 B 11 592 M 11 592 M
Net income 2022 194 B 1 697 M 1 697 M
Net cash 2022 584 B 5 108 M 5 108 M
P/E ratio 2022 18,8x
Yield 2022 2,53%
Capitalization 3 669 B 32 115 M 32 108 M
EV / Sales 2022 2,33x
EV / Sales 2023 2,09x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 980,00 JPY
Average target price 2 486,15 JPY
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.24.22%32 494
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657